Abstract:Objective To observe the effects and safety of quadruple regimens including domestically manufactured rabeprazole used as first line/initial therapy for Helicobacter pylori ( H.pylori ) eradication in gastritis and duodenal ulcer patients, and to investigate the effects of extended use of bismuth after the quadruple therapy on eradication of H.pylori.Methods From January to August 2013, 430 patients with chronic gastritis or duodenal ulcer who were confirmed as H.pylori positive in gastroscopy for upper gastrointestinal symptoms were enrolled from 12 centers in China for initial treatment using quadruple regimens for H.pylori eradication.The study was a prospective, multicenter, randomized double-blinded double-dummy parallel-controlled clinical trial.The 310 chronic gastritis patients were divided into 2 groups:group A1 was given quadruple regime ( rabeprazole +amoxicillin +clarithromycin +bismuth potassium citrate) for 10 days followed by bismuth-placebo for 21 days;group A2 was given the quadruple regimen for 10 days and then bismuth potassium citrate for 21 days.The duodenal ulcer patients were given the quadruple for 10 days, then rabeprazole for 14 days.All the patients took 13 C urea breath test to detect H.pylori 28 days after medicine withdrawal.Results Altogether 428 cases were enrolled and 404 completed the trial.The total eradication rate in the chronic gastritis patients was 85.1%(262/308, intention-to-treat (ITT)analysis), which was 81.7%(125/153, ITT) in the A1 group and 88.4%(137/155, ITT) in the A2 group;the eradication rate in the duodenal ulcer patients was 85.8% (103/120, ITT).No severe adverse effects were reported.The symptoms ( pain, burning sensation, reflux, belching, nausea, and vomiting) improvement status was similar among A1 and A2 groups.Conclusions The quadruple regimen using rabeprazole manufactured in China and administered for 10 days as first line/initial therapy in chronic gastritis and duodenal ulcer patients could achieve good H.pylori eradication rate.The extended use of bismuth after 10-day quadruple regimen might further improve the eradication rate.The regimens containing proton-pump inhibitor and bismuth may be well tolerated and safe in clinical application.

Vonoprazan-based triple and dual therapy versus bismuth-based quadruple therapy for Helicobacter pylori infection in China: a three-arm, randomised clinical trial protocol

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Efficacy and Safety of Vonoprazan-based Treatment of Helicobacter Pylori Infection: a Systematic Review and Network Meta-Analysis

Vonoprazan Dual or Triple Therapy Versus Bismuth‐Quadruple Therapy as First‐Line Therapy for Helicobacter pylori Infection: A Three‐Arm, Randomized Clinical Trial

Comparison of vonoprazan bismuth‐containing triple therapy with quadruple therapy in Helicobacter pylori‐infected treatment‐naive patients: a prospective multicenter randomized controlled trial

Pharmacokinetics, Safety, and Tolerability of Vonoprazan‐ or Esomeprazole‐Based Bismuth‐Containing Quadruple Therapy: A Phase 1, Double‐Blind, Parallel‐Group Study in Adults with Helicobacter pylori Infection in China

Ten-Day Bismuth-Containing Quadruple Therapy is Effective As First-Line Therapy for Helicobacter Pylori-Related Chronic Gastritis: A Prospective Randomized Study in China

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for Helicobacter pylori infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Efficacy and Safety of Vonoprazan-Based Quadruple Therapy for the Eradication of Helicobacter pylori in Patients with Peptic Ulcers: A Pooled Analysis of Two Randomized, Double-Blind, Double-Dummy, Phase 3 Trials

Comparison of vonoprazan-based dual therapy with vonoprazan-based bismuth quadruple therapy for treatment-naive patients with Helicobacter pylori infection: A propensity score matching analysis

The efficacy and mechanism of vonoprazan-containing triple therapy in the eradication of Helicobacter pylori

Comparison of vonoprazan dual therapy, quadruple therapy and standard quadruple therapy for Helicobacter pylori infection in Hainan: a single-center, open-label, non-inferiority, randomized controlled trial

Eradication rate and safety of vonoprazan-amoxicillin dual therapy for helicobacter pylori eradication: a randomized controlled trial

Quadruple regimens using domestically manufactured drugs in gastritis and duodenal ulcer patients for Helicobacter pylori eradication:a perspective, multicenter, randomized controlled trial

Eradication rates of Helicobacter pylori in treatment‐naive patients following 14‐day vonoprazan‐amoxicillin dual therapy: A multicenter randomized controlled trial in China

A Modified 14-Day Dual Therapy with Vonoprazan and Amoxicillin Amplified the Advantages Over Conventional Therapies for Eradication of Helicobacter pylori: A Non-Inferiority Clinical Trial

New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese prospective, randomized, multicentre trial.

Efficacy of quadruple regimen with polaprezinc for gastric Helicobacter pylori infection eradication: protocol for a single-centre, single-blind, non-inferiority, randomised clinical trial

A Placebo-Controlled Trial of 10-Day Bismuth-Based Quadruple Therapy to Eradicate Helicobacter Pylori Infection; a Pilot Study for the Large Linqu County Trial